BCL2 and B-cell chronic lymphocytic leukemia: The presence of TP53 mutations also predicts poor response to standard chemoimmunotherapy, necessitating the use of novel targeted agents such as Bruton’s tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib) and B-cell lymphoma 2 (BCL-2) inhibitors (venetoclax), which have demonstrated superior efficacy in TP53-mutated CLL [179,180].